Literature DB >> 6354201

The cytodynamics of endometrial hyperplasia and carcinoma. A review.

A Ferenczy, M M Gelfand, F Tzipris.   

Abstract

Current evidence suggests that endometrial hyperplasia represents a spectrum of increasingly atypical proliferation of glands and their lining epithelium that is correlated with increasing persistence, recurrence and progression rates, to carcinoma following curettage and/or progestagen therapy. Hyperplasia can be divided into two phases of pathogenetic development. An initial proliferative phase leading to hypertrophy and a second or remodelling phase, characterized by increasing morphokinetic and biochemical alterations of gland cells. Histologically, the proliferative phase is classified into anovulatory, persistent proliferative endometrium and cystic glandular hyperplasia and the remodelling phase, into adenomatous hyperplasia without and with significant cytologic atypia. The histologic subsets can further be classified as mild, moderate and severe hyperplasia according to their respective clinical behaviour. The data suggest, furthermore, that endometrial C.I.S. represents a transitional state between severe hyperplasia and early, invasive adenocarcinoma. From a pathogenetic standpoint, hyperplasia is induced by longstanding, unopposed estrogenic stimulation and its early phase is made of estradiol-sensitive cells. Paralleling the gradual increase in architectural and cytologic atypia, clones of cells are produced that are relatively insensitive to estradiol and have impaired response to growth-control mechanisms. These estradiol-independent cells are presumably susceptible to malignant transformation.

Entities:  

Mesh:

Year:  1983        PMID: 6354201

Source DB:  PubMed          Journal:  Ann Pathol        ISSN: 0242-6498            Impact factor:   0.407


  4 in total

1.  Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway.

Authors:  A Orbo; J P Baak; I Kleivan; S Lysne; P S Prytz; M A Broeckaert; A Slappendel; H J Tichelaar
Journal:  J Clin Pathol       Date:  2000-09       Impact factor: 3.411

2.  Novel, orally active selective progesterone receptor modulator CP8947 inhibits leiomyoma cell proliferation without adversely affecting endometrium or myometrium.

Authors:  William H Catherino; Minnie Malik; Paul Driggers; Scott Chappel; James Segars; Joseph Davis
Journal:  J Steroid Biochem Mol Biol       Date:  2010-05-20       Impact factor: 4.292

3.  Estrone sulfatase activity in normal and abnormal endometrium.

Authors:  G L Adessi; O Prost; G Agnani; A Petitjean; J Burnod
Journal:  Arch Gynecol       Date:  1984

Review 4.  Regulation of human endometrial function: mechanisms relevant to uterine bleeding.

Authors:  Hilary O D Critchley; Rodney W Kelly; David T Baird; Robert M Brenner
Journal:  Reprod Biol Endocrinol       Date:  2006       Impact factor: 5.211

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.